Join Me For Coffee: Lori Rudolph-Owen, Senior Vice-President, R&D Strategy and Operations, Goldfinch Bio

This event series is exclusive to MASS AWIS members registered with National AWIS,

with paid Massachusetts chapter dues or a MASS AWIS student chapter member.

Join MASS AWIS today for access to this series and other exclusive opportunities.

MASS AWIS is offering its members an exclusive opportunity to make professional connections across a variety of career paths. ‘Join Me for Coffee’ gives a chance to meet with a STEM professional for 1 hour at a coffee shop or café. Participants will not only learn about that person’s career but also establish a new professional connection. These events are a great opportunity for participants to practice networking in an intimate setting, a skill that helps open doors to meaningful careers in STEM. Snacks and beverages will be provided.

The upcoming ‘Join Me for Coffee’ event series will feature Lori Rudolph-Owen (bio below). If you would like to participate in this ‘Join Me for Coffee’ event, first complete the event application form. A committee will then review all applications and select 4-6 participants for each event. Selected applicants will be notified by email at least one week prior to the event. Upon selection notification, you will be required to formally register for the event and pay the registration fee via our secure website. Selected applicants who fail to complete registration on time forfeit the opportunity to participate.

Guest Bio

Senior Vice-President, R&D Strategy and Operations, Goldfinch Bio

Dr. Lori Rudolph-Owen brings over 20 years of leadership experience in pharmaceutical and biotechnology R&D, specifically in strategic planning, program leadership, development operations, and driving effective cross-functional collaboration. Lori joined Goldfinch Bio in February of 2018 and is currently the Senior Vice President of R&D Strategy and Operations.

Prior to joining Goldfinch, Lori served at the Vice President of Portfolio Management and Assessment at TESARO, Inc where she developed and led a team of  Development Program Team Leaders, Portfolio Managers and Competitive Intelligence professionals to support the submission, approval and launch for 3 US and 2 European oncology products as well as the filing of 3 INDs. She also held positions of increasing drug development leadership responsibility at Pfizer, AMAG Pharmaceuticals, Abraxis BioScience (now Celgene), MGI Pharma (now Eisai), and Vertex.

Dr. Rudolph-Owen received her PhD in Cell Biology at Vanderbilt University. After completing a postdoctoral fellowship, she moved to Boston to join Millennium Pharmaceuticals as an Oncology Discovery Scientist before transitioning over to Drug Development Program Leadership at Vertex.

Application deadline: April 12th, 2020 at 11:55 PM

Registration fee (upon acceptance): $5